FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068757580> ?p ?o ?g. }

• W2068757580 endingPage "S225" @default.
• W2068757580 startingPage "S224" @default.
• W2068757580 abstract "Emerging clinical data suggest that high-dose PT/Cy is effective in preventing both acute and chronic GVHD, but the mechanisms accounting for these effects have not been fully characterized. We hypothesized that PT/Cy prevents acute GVHD (aGVHD) by selectively depleting highly proliferative alloreactive T cells stimulated early after transplant, while sparing Tregs. We analyzed the phenotypic reconstitution of CD4+ T cells at days 30 and 60 after transplant in a cohort of 47 consecutive patients (median age 50) that received HLA-matched allografts and PT/Cy as sole GVHD prophylaxis. CD4+Foxp3+ T cells were partitioned into three phenotypic fractions (Fr) with distinct functions: CD45RA+Foxp3+lo (Fr I), CD45RA-Foxp3+hi (Fr II), and CD45RA-Foxp3+lo (Fr III), representing naive Tregs, activated Tregs, and non-suppressive, cytokine-secreting Teff, respectively. In both patients with and without aGHVD, Teff (Fr III) percentages were increased compared with healthy donors (p = 0.004), and were higher in patients with aGVHD compared with patients without aGVHD (p = 0.0003). Interestingly, patients with aGVHD also had higher percentages of activated Tregs (Fr II, p = 0.01) compared with patients without aGVHD. These relative increases in Fr II and III persisted despite steroid-induced lymphopenia. The relative expansion of Tregs in patients with aGVHD was an unexpected finding, since aGVHD is associated with lower Tregs in studies using traditional GVHD prophylaxis incorporating calcineurin inhibitors (CNIs). To assess differential effects of PT/Cy and CNI on T cell reconstitution in alloreactive responses, mixed lymphocyte reactions (MLR) were performed (n = 6). High-dose, activated cyclophosphamide (mafosfamide) given 3 days after the start of MLR caused increases in Fr I-III at 7 days (Fr II, p<0.0001; Fr III, p = 0.0002), while cyclosporine-treated cells had similar to lower levels of these fractions compared with controls. The addition of mafosfamide at day 3 to cyclosporine-cultured cells in MLR caused similar increases in Fr I and III as seen with mafosfamide alone, but the Fr II increase was no longer significant. In summary, T cell reconstitution in patients treated with PT/Cy differs from that seen with CNI-based GVHD prophylaxis. For patients treated with PT/Cy who still develop aGVHD, relative expansion of Tregs may be a critical compensatory mechanism accounting for the remarkably low incidence of chronic GVHD seen in these patients. Emerging clinical data suggest that high-dose PT/Cy is effective in preventing both acute and chronic GVHD, but the mechanisms accounting for these effects have not been fully characterized. We hypothesized that PT/Cy prevents acute GVHD (aGVHD) by selectively depleting highly proliferative alloreactive T cells stimulated early after transplant, while sparing Tregs. We analyzed the phenotypic reconstitution of CD4+ T cells at days 30 and 60 after transplant in a cohort of 47 consecutive patients (median age 50) that received HLA-matched allografts and PT/Cy as sole GVHD prophylaxis. CD4+Foxp3+ T cells were partitioned into three phenotypic fractions (Fr) with distinct functions: CD45RA+Foxp3+lo (Fr I), CD45RA-Foxp3+hi (Fr II), and CD45RA-Foxp3+lo (Fr III), representing naive Tregs, activated Tregs, and non-suppressive, cytokine-secreting Teff, respectively. In both patients with and without aGHVD, Teff (Fr III) percentages were increased compared with healthy donors (p = 0.004), and were higher in patients with aGVHD compared with patients without aGVHD (p = 0.0003). Interestingly, patients with aGVHD also had higher percentages of activated Tregs (Fr II, p = 0.01) compared with patients without aGVHD. These relative increases in Fr II and III persisted despite steroid-induced lymphopenia. The relative expansion of Tregs in patients with aGVHD was an unexpected finding, since aGVHD is associated with lower Tregs in studies using traditional GVHD prophylaxis incorporating calcineurin inhibitors (CNIs). To assess differential effects of PT/Cy and CNI on T cell reconstitution in alloreactive responses, mixed lymphocyte reactions (MLR) were performed (n = 6). High-dose, activated cyclophosphamide (mafosfamide) given 3 days after the start of MLR caused increases in Fr I-III at 7 days (Fr II, p<0.0001; Fr III, p = 0.0002), while cyclosporine-treated cells had similar to lower levels of these fractions compared with controls. The addition of mafosfamide at day 3 to cyclosporine-cultured cells in MLR caused similar increases in Fr I and III as seen with mafosfamide alone, but the Fr II increase was no longer significant. In summary, T cell reconstitution in patients treated with PT/Cy differs from that seen with CNI-based GVHD prophylaxis. For patients treated with PT/Cy who still develop aGVHD, relative expansion of Tregs may be a critical compensatory mechanism accounting for the remarkably low incidence of chronic GVHD seen in these patients." @default.
• W2068757580 created "2016-06-24" @default.
• W2068757580 creator A5010727267 @default.
• W2068757580 creator A5014659694 @default.
• W2068757580 creator A5021849583 @default.
• W2068757580 creator A5036664711 @default.
• W2068757580 creator A5060234674 @default.
• W2068757580 creator A5065373363 @default.
• W2068757580 creator A5065451110 @default.
• W2068757580 creator A5082236040 @default.
• W2068757580 creator A5088162141 @default.
• W2068757580 date "2012-02-01" @default.
• W2068757580 modified "2023-09-23" @default.
• W2068757580 title "Post-Transplant Cyclophosphamide (PT/Cy) Preserves Effector (Teff) and Regulatory (Treg) T Cells During Early Immune Reconstitution After Allogeneic Bone Marrow Transplantation" @default.
• W2068757580 doi "https://doi.org/10.1016/j.bbmt.2011.12.065" @default.
• W2068757580 hasPublicationYear "2012" @default.
• W2068757580 type Work @default.
• W2068757580 sameAs 2068757580 @default.
• W2068757580 citedByCount "1" @default.
• W2068757580 countsByYear W20687575802012 @default.
• W2068757580 crossrefType "journal-article" @default.
• W2068757580 hasAuthorship W2068757580A5010727267 @default.
• W2068757580 hasAuthorship W2068757580A5014659694 @default.
• W2068757580 hasAuthorship W2068757580A5021849583 @default.
• W2068757580 hasAuthorship W2068757580A5036664711 @default.
• W2068757580 hasAuthorship W2068757580A5060234674 @default.
• W2068757580 hasAuthorship W2068757580A5065373363 @default.
• W2068757580 hasAuthorship W2068757580A5065451110 @default.
• W2068757580 hasAuthorship W2068757580A5082236040 @default.
• W2068757580 hasAuthorship W2068757580A5088162141 @default.
• W2068757580 hasConcept C126322002 @default.
• W2068757580 hasConcept C128057223 @default.
• W2068757580 hasConcept C203014093 @default.
• W2068757580 hasConcept C2776090121 @default.
• W2068757580 hasConcept C2776694085 @default.
• W2068757580 hasConcept C2776755627 @default.
• W2068757580 hasConcept C2778296632 @default.
• W2068757580 hasConcept C2779727006 @default.
• W2068757580 hasConcept C2780007613 @default.
• W2068757580 hasConcept C2911091166 @default.
• W2068757580 hasConcept C71924100 @default.
• W2068757580 hasConcept C79484868 @default.
• W2068757580 hasConcept C8891405 @default.
• W2068757580 hasConceptScore W2068757580C126322002 @default.
• W2068757580 hasConceptScore W2068757580C128057223 @default.
• W2068757580 hasConceptScore W2068757580C203014093 @default.
• W2068757580 hasConceptScore W2068757580C2776090121 @default.
• W2068757580 hasConceptScore W2068757580C2776694085 @default.
• W2068757580 hasConceptScore W2068757580C2776755627 @default.
• W2068757580 hasConceptScore W2068757580C2778296632 @default.
• W2068757580 hasConceptScore W2068757580C2779727006 @default.
• W2068757580 hasConceptScore W2068757580C2780007613 @default.
• W2068757580 hasConceptScore W2068757580C2911091166 @default.
• W2068757580 hasConceptScore W2068757580C71924100 @default.
• W2068757580 hasConceptScore W2068757580C79484868 @default.
• W2068757580 hasConceptScore W2068757580C8891405 @default.
• W2068757580 hasIssue "2" @default.
• W2068757580 hasLocation W20687575801 @default.
• W2068757580 hasOpenAccess W2068757580 @default.
• W2068757580 hasPrimaryLocation W20687575801 @default.
• W2068757580 hasRelatedWork W1510545292 @default.
• W2068757580 hasRelatedWork W2025218024 @default.
• W2068757580 hasRelatedWork W2034441290 @default.
• W2068757580 hasRelatedWork W2121007697 @default.
• W2068757580 hasRelatedWork W2153070516 @default.
• W2068757580 hasRelatedWork W2352803447 @default.
• W2068757580 hasRelatedWork W2418194605 @default.
• W2068757580 hasRelatedWork W2896477433 @default.
• W2068757580 hasRelatedWork W4313348242 @default.
• W2068757580 hasRelatedWork W9652024 @default.
• W2068757580 hasVolume "18" @default.
• W2068757580 isParatext "false" @default.
• W2068757580 isRetracted "false" @default.
• W2068757580 magId "2068757580" @default.
• W2068757580 workType "article" @default.